Alexion's CEO and CFO abruptly departed in December, there's allegation of sales fraud, and its 10-Q for the third quarter remains outstanding. The company really needed some good news, but its Phase 2/3 study of Soliris in delayed graft function just didn't deliver.
Yale spinout Arvinas just raised $41.6 million for its platform of protein degradation drugs - a different mechanism than the standard protein inhibition drugs on the market.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New Haven biotech Trevi Therapeutics is developing a treatment for chronically unscratchable itches – its oral drug is an extended release opioid meant to treat a number of pruritic conditions. These can be quite serious, after all – chronic itching can lead to a markedly reduced quality of life in a number of dermatologic, metabolic, hematologic and neuropathic […]
IsoPlexis, a Yale spinout developing an immunologic assay that helps researchers understand how therapies impact individual patients on a cellular level, seems to have raised a nice chunk of startup capital. The company, formed last year by a couple of MBA candidates, has raised $1.3 million of a $1.7 million early-stage round, according to a […]
Yale spin-off Kolltan Pharmaceuticals has raised $60 million to advance its cancer treatment through clinical trials, according to a Form D filing with the Securities and Exchange Commission. The drug developer sees potential for the drug across breast, lung and ovarian cancers. It also sees the drug as reducing the risk of patients showing resistance […]
A Yale neuroscientist and psychiatry professor has developed an enrichment program that could help children with attention-deficit/hyperactivity disorder stay on task and avoid getting distracted. C8 Sciences has raised the first part of a $1.1 million fundraise in a move the CEO hopes will help it advance product development and build its customer base. The […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Michael Ellison has a tough assignment. He's the associate dean of admissions choosing the first class of a brand new medical school, the Frank H. Netter MD School of Medicine at Quinnipiac University in Connecticut. It’s a school with a very sp...
One of the components of healthcare reform that goes right along with improving outcomes is getting people to take more responsibility for their health — no easy feat, particularly for those with chronic conditions who face a long struggle managing their condition, complicated by underlying conditions like depression. That ramps up the importance of having […]